» Articles » PMID: 32854731

Results Following Surgical Resection of Recurrent Chordoma of the Spine: Experience in a Single Institution

Overview
Publisher Biomed Central
Date 2020 Aug 29
PMID 32854731
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chordoma of the spine is a low-grade malignant tumor with vague and indolent symptoms; thus, large tumor mass is encountered at the time of diagnosis in almost cases and makes it difficult for en-bloc free-margin resection. Salvage therapy for recurrent chordoma is very challenging due to its relentless nature and refractory to adjuvant therapies. The aim of this present study was to report the oncologic outcome following surgical resection of chordoma of the spine.

Materials And Methods: Retrospective review of 10 consecutive cases of recurrent chordoma patients who underwent surgical treatment between 2003 and 2018 at one tertiary-care center was conducted.

Results: There were 10 patients; 4 females and 6 males were included in this study. Eight patients had local recurrence. The recurrence was encountered at the muscle, surrounding soft tissue, and remaining bony structure. Distant metastases were found in 2 patients. The median time to recurrence or metastasis was 30 months after first surgery.

Conclusion: En-bloc free-margin resection is mandatory to prevent recurrence. The clinical vigilance and investigation to identify tumor recurrent should be performed every 3 to 6 months, especially in the first 30 months and annually thereafter. Detection of recurrent in early stage with a small mass may be the best chance to perform an en-bloc margin-free resection to prevent further recurrence.

Citing Articles

Muscle metastasis from cervical chordoma: a case report.

Sekmen S, Hursoy N, Gucer H, Burakgazi G, Balik M, Cubukcu S Skeletal Radiol. 2024; .

PMID: 39259321 DOI: 10.1007/s00256-024-04780-7.


Systematic Review and Meta-Analysis of Particle Beam Therapy versus Photon Radiotherapy for Skull Base Chordoma: TRP-Chordoma 2024.

Saito T, Mizumoto M, Oshiro Y, Shimizu S, Li Y, Nakamura M Cancers (Basel). 2024; 16(14).

PMID: 39061207 PMC: 11274426. DOI: 10.3390/cancers16142569.


Multifocal Ectopic Recurrence of a C2 Chordoma.

Reyes M, Kayne A, Collopy S, Prashant G, Kelly P, Evans J J Neurol Surg Rep. 2023; 84(4):e146-e155.

PMID: 38026145 PMC: 10673705. DOI: 10.1055/s-0043-1777073.


Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma.

Wei J, Wu J, Yin Z, Li X, Liu Y, Wang Y Front Oncol. 2023; 12:1048482.

PMID: 36601478 PMC: 9806209. DOI: 10.3389/fonc.2022.1048482.

References
1.
Chandawarkar R . Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg. 1996; 20(6):717-9. DOI: 10.1007/s002689900110. View

2.
Hanna S, Aston W, Briggs T, Cannon S, Saifuddin A . Sacral chordoma: can local recurrence after sacrectomy be predicted?. Clin Orthop Relat Res. 2008; 466(9):2217-23. PMC: 2493011. DOI: 10.1007/s11999-008-0356-7. View

3.
Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H . Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2004; 42(8):800-8. DOI: 10.1080/02841860310017676. View

4.
Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M . Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003; 10(3):291-6. DOI: 10.1245/aso.2003.06.002. View

5.
Yang Y, Li Y, Liu W, Xu H, Niu X . The clinical outcome of recurrent sacral chordoma with further surgical treatment. Medicine (Baltimore). 2018; 97(52):e13730. PMC: 6314672. DOI: 10.1097/MD.0000000000013730. View